BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 31037185)

  • 1. A diffuse large B cell lymphoma emerging with breast cancer relapse.
    Karismaz A; Dogu MH; Huq G; Altindal S; Yokus O; Suyani E
    Pan Afr Med J; 2018; 31():125. PubMed ID: 31037185
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. Eastern Cooperative Oncology Group.
    Tormey DC; Gray R; Falkson HC
    J Natl Cancer Inst; 1996 Dec; 88(24):1828-33. PubMed ID: 8961972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group.
    Wils JA; Bliss JM; Marty M; Coombes G; Fontaine C; Morvan F; Olmos T; Pérez-López FR; Vassilopoulos P; Woods E; Coombes RC
    J Clin Oncol; 1999 Jul; 17(7):1988-98. PubMed ID: 10561249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
    Jankowitz RC; McGuire KP; Davidson NE
    Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.
    Fisher B; Dignam J; Bryant J; DeCillis A; Wickerham DL; Wolmark N; Costantino J; Redmond C; Fisher ER; Bowman DM; Deschênes L; Dimitrov NV; Margolese RG; Robidoux A; Shibata H; Terz J; Paterson AH; Feldman MI; Farrar W; Evans J; Lickley HL
    J Natl Cancer Inst; 1996 Nov; 88(21):1529-42. PubMed ID: 8901851
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy.
    Zhang B; Zhang X; Li M; Kong L; Deng X; Yu J
    Cancer Biol Ther; 2016; 17(2):125-8. PubMed ID: 26861804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant percutaneous 4-hydroxytamoxifen decreases breast tumoral cell proliferation: a prospective controlled randomized study comparing three doses of 4-hydroxytamoxifen gel to oral tamoxifen.
    Rouanet P; Linares-Cruz G; Dravet F; Poujol S; Gourgou S; Simony-Lafontaine J; Grenier J; Kramar A; Girault J; Le Nestour E; Maudelonde T
    J Clin Oncol; 2005 May; 23(13):2980-7. PubMed ID: 15860853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Caring for the breast cancer survivor.
    Abdel-Razeq H
    Am J Med; 2011 Feb; 124(2):e11; author reply e13. PubMed ID: 21295181
    [No Abstract]   [Full Text] [Related]  

  • 10. A breast cancer patient with myelodysplastic syndrome postoperatively treated by radiation and tamoxifen administration--a case report.
    Mitani N; Sakuragi S; Matsuda K; Tanaka Y; Matsui K; Shinohara K
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):833-6. PubMed ID: 16770108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three cases of malignant lymphoma of the breast.
    Suzuki Y; Tokuda Y; Okumura A; Saito Y; Ohta M; Kubota M; Makuuchi H; Tajima T; Umemura S; Osamura RY
    Jpn J Clin Oncol; 2000 Jan; 30(1):33-6. PubMed ID: 10770567
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary diffuse large B cell lymphoma of the breast eight years after the diagnosis of gastric MALT lymphoma: report of first case.
    Bilici A; Ozguroglu M; Tuzuner N; Goksel S; Turna H
    Arch Gynecol Obstet; 2010 Nov; 282(5):587-90. PubMed ID: 20419308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
    Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
    Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
    Margolese RG; Cecchini RS; Julian TB; Ganz PA; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
    Lancet; 2016 Feb; 387(10021):849-56. PubMed ID: 26686957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uterine sarcoma after tamoxifen therapy for breast cancer.
    Samuji M; O'Sullivan R; Shireen R
    Ir Med J; 2013 Sep; 106(8):246. PubMed ID: 24282897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer.
    Fyles AW; McCready DR; Manchul LA; Trudeau ME; Merante P; Pintilie M; Weir LM; Olivotto IA
    N Engl J Med; 2004 Sep; 351(10):963-70. PubMed ID: 15342804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
    Howell A; Cuzick J; Baum M; Buzdar A; Dowsett M; Forbes JF; Hoctin-Boes G; Houghton J; Locker GY; Tobias JS;
    Lancet; 2005 Jan 1-7; 365(9453):60-2. PubMed ID: 15639680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stroke risk and tamoxifen therapy for breast cancer.
    Geiger AM; Fischberg GM; Chen W; Bernstein L
    J Natl Cancer Inst; 2004 Oct; 96(20):1528-36. PubMed ID: 15494603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6.
    Schmid M; Jakesz R; Samonigg H; Kubista E; Gnant M; Menzel C; Seifert M; Haider K; Taucher S; Mlineritsch B; Steindorfer P; Kwasny W; Stierer M; Tausch C; Fridrik M; Wette V; Steger G; Hausmaninger H
    J Clin Oncol; 2003 Mar; 21(6):984-90. PubMed ID: 12637461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Insights Into Nonadherence With Adjuvant Endocrine Therapy Among Young Women With Breast Cancer.
    Rosenberg SM; Partridge AH
    J Natl Cancer Inst; 2015 Oct; 107(10):. PubMed ID: 26307642
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.